CELLULAR AND VIRAL REGULATION OF TYPE III EBV LATENCY
III 型 EBV 潜伏期的细胞和病毒调控
基本信息
- 批准号:6930188
- 负责人:
- 金额:$ 21.92万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-04-01 至 2010-03-31
- 项目状态:已结题
- 来源:
- 关键词:B lymphocyteEpstein Barr virusHerpesviridae diseasebiological signal transductioncadherinscell cyclecell differentiationcyclin dependent kinasegene expressiongenetic regulationhost organism interactionlatent virus infectionlymphocyte proliferationoncogenic virusphosphorylationubiquitinviral carcinogenesisvirus antigenvirus cytopathogenic effect
项目摘要
Characteristic of EBV as a human tumor virus is its ability to immortalize B-lymphocytes and establish different degrees of latency. EBV latency products regulate cell-signaling pathways important in cell-cycle progression. Here we propose that cell-signaling molecules regulate the expression of EBV products in a cell-cycle-dependent manner. EBNA-2 is the master regulator of all the promoters used in Type III latency. We show that EBNA-2 is specifically hyperphosphorylated in M phase of the cell cycle, which correlates with suppression of Type III
promoter activities. These observations indicate that there may be general inhibition of EBNA-2's transactivation functions in mitosis. In Aim I we examine regulation of type III latency products during the cell cycle in relation to EBNA-2 phosphorylation status. We have implicated p34/cdc2 kinase in EBNA-2 hyperphosphorylation during M phase and identified a phosphorylation site of EBNA-2 specific for this kinase. We will determine the biological role of this site and also identify other sites of EBNA-2 phosphorylation in M phase through mutational analysis. EBV infection affects important cell-signaling pathways. Recently we discovered that EBV induces the beta-catenin/Tcf pathway, a key cellular oncogenic pathway, in type III latency. In Aim II we examine how the latent EBV infection state critically alters this pathway and will investigate whether it is essential for immortalization of B-cells by EBV. We will examine if inhibition of this pathway leads to growth arrest and differentiation in EBV-immortalized B-lymphocytes. Finally, in Aim III, based on other discoveries, namely, involvement of both deubiquitination and ubiquitination in beta-catenin stabilization, we will bring together these viral and cellular
mechanisms, since they are likely to be involved in EBV oncogenesis. Specifically, we will dissect the mechanism of beta-catenin stabilization in type III latency, focusing on the role of EBNA-2 in deubiquitination, and LMP-1 in ubiquitination. Dysregulation of the balance between these two key proteasomal regulatory processes is likely to be a general phenomenon whereby tumor viruses modulate signaling pathways of host cells.
EBV作为人类肿瘤病毒的特征是其使B淋巴细胞永生化并建立不同程度的潜伏期的能力。EBV潜伏产物调节细胞周期进程中重要的细胞信号传导途径。在这里,我们提出,细胞信号分子调节EBV产品的表达在细胞周期依赖性的方式。EBNA-2是III型潜伏期中使用的所有启动子的主要调节因子。我们发现EBNA-2在细胞周期的M期特异性过度磷酸化,这与III型胶原的抑制有关。
促进活动。这些观察结果表明,在有丝分裂中可能存在EBNA-2的反式激活功能的普遍抑制。在目的I中,我们研究了在细胞周期中与EBNA-2磷酸化状态相关的III型潜伏产物的调节。我们已经暗示p34/cdc 2激酶在M期EBNA-2过度磷酸化,并确定了EBNA-2特异性磷酸化位点。我们将确定该位点的生物学作用,并通过突变分析确定M期EBNA-2磷酸化的其他位点。EBV感染影响重要的细胞信号传导途径。最近,我们发现EB病毒诱导β-连环蛋白/Tcf通路,一个关键的细胞致癌途径,在III型潜伏期。在目的II中,我们研究了潜伏的EBV感染状态如何严重改变这一途径,并将研究它是否是EBV永生化B细胞所必需的。我们将研究是否抑制这一途径导致生长停滞和分化的EBV永生化B淋巴细胞。最后,在Aim III中,基于其他发现,即去泛素化和泛素化参与β-连环蛋白的稳定,我们将把这些病毒和细胞
它们可能参与EBV的致癌机制。具体来说,我们将剖析β-连环蛋白在III型潜伏期中的稳定机制,重点是EBNA-2在去泛素化中的作用,以及LMP-1在泛素化中的作用。这两个关键蛋白酶体调节过程之间的平衡失调可能是肿瘤病毒调节宿主细胞信号传导途径的普遍现象。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOSEPH S PAGANO其他文献
JOSEPH S PAGANO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOSEPH S PAGANO', 18)}}的其他基金
PREVENTION AND ANTIVIRAL TREATMENT FOR EBV LYMPHOMAGENESIS
EBV 淋巴生成的预防和抗病毒治疗
- 批准号:
8502416 - 财政年份:2012
- 资助金额:
$ 21.92万 - 项目类别:
PREVENTION AND ANTIVIRAL TREATMENT FOR EBV LYMPHOMAGENESIS
EBV 淋巴生成的预防和抗病毒治疗
- 批准号:
8410979 - 财政年份:2012
- 资助金额:
$ 21.92万 - 项目类别:
CELLULAR REGULATION OF TYPE III EBV LATENCY
III 型 EBV 潜伏期的细胞调节
- 批准号:
6642890 - 财政年份:2002
- 资助金额:
$ 21.92万 - 项目类别:
CELLULAR REGULATION OF TYPE III EBV LATENCY
III 型 EBV 潜伏期的细胞调节
- 批准号:
6493592 - 财政年份:2001
- 资助金额:
$ 21.92万 - 项目类别:
相似海外基金
Project 4 - Controlling the Latent-to-Lytic Switch in Epstein-Barr Virus
项目 4 - 控制 Epstein-Barr 病毒中的潜伏至裂解转换
- 批准号:
10910338 - 财政年份:2023
- 资助金额:
$ 21.92万 - 项目类别:
Epstein-Barr Virus nuclear antigen leader protein in transcription regulation
Epstein-Barr病毒核抗原前导蛋白在转录调控中的作用
- 批准号:
10829620 - 财政年份:2023
- 资助金额:
$ 21.92万 - 项目类别:
Exploiting Metabolism to Uncloak Epstein-Barr Virus Immunogens in Latently Infected B-cells
利用代谢揭示潜伏感染 B 细胞中的 Epstein-Barr 病毒免疫原
- 批准号:
10889325 - 财政年份:2023
- 资助金额:
$ 21.92万 - 项目类别:
Understanding the immune response changes to clinical interventions for Epstein-Barr virus infection prior to lymphoma development in children after organ transplants (UNEARTH)
了解器官移植后儿童淋巴瘤发展之前针对 Epstein-Barr 病毒感染的临床干预的免疫反应变化(UNEARTH)
- 批准号:
10755205 - 财政年份:2023
- 资助金额:
$ 21.92万 - 项目类别:
Regulation and Functions of the Epstein-Barr Virus Lytic Switch Protein
EB 病毒裂解开关蛋白的调控和功能
- 批准号:
489085 - 财政年份:2023
- 资助金额:
$ 21.92万 - 项目类别:
Operating Grants
Characterization of Epstein-Barr Virus Subversion of the Host SMC5/6 Restriction Pathway
Epstein-Barr 病毒颠覆宿主 SMC5/6 限制途径的特征
- 批准号:
10679118 - 财政年份:2023
- 资助金额:
$ 21.92万 - 项目类别:
Epstein Barr Virus Driven Mechanisms of Post Transplant Lymphoproliferative Disease
EB 病毒驱动的移植后淋巴增殖性疾病的机制
- 批准号:
10755055 - 财政年份:2023
- 资助金额:
$ 21.92万 - 项目类别:
Deciphering the Role of Epstein-Barr Virus Molecular Mimicry and B cell Transformation in Multiple Sclerosis
解读 Epstein-Barr 病毒分子拟态和 B 细胞转化在多发性硬化症中的作用
- 批准号:
10568864 - 财政年份:2023
- 资助金额:
$ 21.92万 - 项目类别:
Project 2: Novel investigation of Epstein-Barr virus as a potential cause of conjunctival squamous cell carcinoma among people living with HIV in Zimbabwe
项目 2:对 Epstein-Barr 病毒作为津巴布韦艾滋病毒感染者结膜鳞状细胞癌潜在原因的新调查
- 批准号:
10598376 - 财政年份:2023
- 资助金额:
$ 21.92万 - 项目类别:
Project 3 - Characterizing the Amplification Factories of Epstein-Barr Virus and Kaposi's Sarcoma-associated Herpesvirus
项目 3 - 描述 Epstein-Barr 病毒和卡波西肉瘤相关疱疹病毒的扩增工厂
- 批准号:
10910337 - 财政年份:2023
- 资助金额:
$ 21.92万 - 项目类别: